This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why You Should Hold Humana (HUM) Stock in Your Portfolio
by Zacks Equity Research
Humana (HUM) rides high on solid Medicare business growth and its strategic efforts. The stock holds immense potential to reap solid benefits for investors.
The Zacks Analyst Blog Highlights: Walmart, American Tower, U.S. Bancorp, Humana and Royal Caribbean
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walmart, American Tower, U.S. Bancorp, Humana and Royal Caribbean
Top Research Daily Reports for Walmart, American Tower & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), American Tower (AMT) and U.S. Bancorp (USB).
Humana (HUM) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 4.19% and 1.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Q1 Earnings & Revenues Beat Estimates, SurgeY/Y
by Zacks Equity Research
Humana's (HUM) first-quarter earnings benefit from Medicare Advantage membership growth and robust revenues.
Humana's (HUM) Q1 Earnings and Revenue Beat Estimates
by Zacks Equity Research
Humana's (HUM) first quarter earnings gain on the back of higher revenues.
Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?
by Zacks Equity Research
Humana's (HUM) Q1 earnings are likely to gain on higher membership and a solid Medicare Advantage.
Is a Beat in the Cards for Molina's (MOH) Earnings in Q1?
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 earnings will gain from membership growth and its streamlining efforts. However, the same might be partially offset by contract losses and the company's Marketplace business.
Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Universal Health's (UHS) first-quarter earnings are affected by a pre-tax unrealized loss.
What's in Store for HCA Healthcare's (HCA) Q1 Earnings?
by Zacks Equity Research
HCA Healthcare (HCA) is likely to gain from higher admissions. However, escalating expenses might weigh down its margins.
Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings?
by Zacks Equity Research
WellCare Health's (WCG) first-quarter earnings are likely to gain from a rise in membership, partly offset by high debt load.
Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Tenet Healthcare (THC) is likely to be hit by declining revenues in the first quarter of 2019.
Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q1 earnings surge on the back of a solid operating performance and strong growth across all core businesses.
Humana (HUM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for Universal Health (UHS) Q1 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q1 is likely to gain traction from higher admissions as well as licensed beds. However, the same might be partially offset by escalating costs.
Centene's (CNC) Q1 Earnings Beat Estimates, Increase Y/Y
by Zacks Equity Research
Centene's (CNC) first-quarter earnings top on solid revenue growth.
Bright Near-Term Outlook for Medical Info Systems Industry
by Sweta Jaiswal
The wave of digital transition is helping players in the Zacks Medical Info Systems industry to open up bountiful opportunities for investors.
Is a Beat in the Cards for Anthem's (ANTM) Q1 Earnings?
by Zacks Equity Research
Anthem's (ANTM) first-quarter earnings are likely to benefit from an impressive operating performance and robust revenues, driven by its strong businesses.
Is a Beat in the Cards for Centene's (CNC) Q1 Earnings?
by Zacks Equity Research
Centene's (CNC) Q1 earnings are likely to gain from its solid Government and Medicaid businesses.
Why Humana (HUM) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Analyst Blog Highlights: McDonald's, Enterprise Products Partners, Charles Schwab, BB&T and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McDonald's, Enterprise Products Partners, Charles Schwab, BB&T and Humana
Healthcare Stocks in Focus on Regulatory and Political Risk
by Sapna Bagaria
Healthcare stocks suffered declines in the Medicare-for-All policy and revving up of drug price rebate.
Centene on Track With Inorganic Strategies to Aid Growth
by Zacks Equity Research
A number of successful acquisitions over the years should aid Centene's (CNC) overall growth.
Top Research Reports for McDonald's, Enterprise Products & Charles Schwab
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), Enterprise Products Partners (EPD) and Charles Schwab (SCHW).
2020 Medicare Rate Exceeds Proposal, Health Insurers to Gain
by Sapna Bagaria
A higher rate of Medicare Advantage reimbursement will benefit health insurers having exposure to this business.